Kedrion
is an Italy-based biopharmaceutical company that develops plasma-based therapies for the treatment of hemophilia and autoimmune diseases... Read moreKedrion
is an Italy-based biopharmaceutical company that develops plasma-based therapies for the treatment of hemophilia and autoimmune diseases... Read more
News
Jul 14, 2026
PR Newswire
Press Release: Kedrion : Kedrion Biopharma Advances Rare Disease Scientific Evidence Generation at ISTH 2026
Jun 01, 2026
StreetInsider
Press Release: Kedrion : /C O R R E C T I O N -- Kedrion Biopharma/
May 04, 2026
PR Newswire
Press Release: Kedrion : Kedrion Highlights Commitment to Rare and UltraRare Diseases on Plasminogen Deficiency Awareness Day
Mar 06, 2026
PR Newswire
Press Release: Kedrion : Kedrion Activates Nationwide Distribution Network for QIVIGY in the U.S.
Nov 28, 2025
Pharmabiz
Kedrion: EMA grants Orphan Drug Designation to Kedrion Biopharma's plasmaderived treatment for aceruloplasminemia, a rare genetic disorder of iron metabolism
Nov 06, 2025
FinanzNachrichten
Kedrion: Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care
Oct 09, 2025
PR Newswire
Press Release: Kedrion : YIMMUGO Now Available in the U.S.: Kedrion Biopharma Commercializes a New Ig Therapy for PI
Oct 01, 2025
Pharmabiz
Kedrion: Kedrion Biopharma receives US FDA approval for Qivigy to treat adults with primary humoral immunodeficiency
Sep 29, 2025
FiercePharma
Kedrion: <a href="https://www.fiercepharma.com/pharma/italian-plasma-specialist-kedrion-reveals-us-investment-plan-after-gaining-fda-nod" hreflang="en">Italian plasma specialist Kedrion reveals US investment plan after gaining FDA nod for Qivigy</a>
May 06, 2025
PR Newswire
Press Release: Kedrion : Kedrion Raises Awareness Around Plasminogen Deficiency
Kedrion Competitors
1
2
3
4
5
6
7
8
9
10